Showing results (101-110 of 760) with videos related to
Sort By:
Pageof 76
Cell Cycle (Georgetown, Tex.)|January 19, 2005
Proteasome inhibition in the treatment of cancerPaul G Richardson, Constantine Mitsiades, Teru Hideshima, et al.British Journal of Haematology|January 18, 2006
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myelomaHiroshi Yasui, Teru Hideshima, Paul G Richardson, et al.Expert Review of Anticancer Therapy|April 13, 2007
Targeting the vascular endothelial growth factor pathway in the treatment of multiple myelomaKlaus Podar, Paul G Richardson, Dharminder Chauhan, et al.Current Medicinal Chemistry. Anti-Cancer Agents|April 8, 2003
Telomerase inhibitors as anticancer therapyMasaharu Akiyama, Teru Hideshima, Nikhil C Munshi, et al.Oncology (Williston Park, N.Y.)|March 2, 2006
New treatments for multiple myelomaPaul G Richardson, Robert Schlossman, Teru Hideshima, et al.Cancer Journal (Sudbury, Mass.)|March 16, 2002
Arsenic trioxide in multiple myeloma: rationale and future directionsKenneth C Anderson, Lawrence H Boise, Robert Louie, et al.Therapeutics and Clinical Risk Management|August 30, 2008
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myelomaTeru Hideshima, Noopur Raje, Paul G Richardson, et al.European Journal of Haematology|October 15, 2010
Emerging therapies for the treatment of relapsed or refractory multiple myelomaMeletios A Dimopoulos, Jesus F San-Miguel, Kenneth C AndersonDrug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|July 16, 2005
Perspectives for combination therapy to overcome drug-resistant multiple myelomaLaurence Catley, Yu-Tzu Tai, Dharminder Chauhan, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
The emerging role of novel therapies for the treatment of relapsed myelomaPaul G Richardson, Teru Hideshima, Constantine Mitsiades, et al.Pageof 76